Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.74
SUPN's Cash to Debt is ranked higher than
75% of the 897 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. SUPN: 2.74 )
SUPN' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 2.74

Equity to Asset 0.52
SUPN's Equity to Asset is ranked higher than
62% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SUPN: 0.52 )
SUPN' s 10-Year Equity to Asset Range
Min: -2.25   Max: 0.61
Current: 0.52

-2.25
0.61
F-Score: 4
Z-Score: 3.58
M-Score: 29.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 8.02
SUPN's Operating margin (%) is ranked higher than
73% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. SUPN: 8.02 )
SUPN' s 10-Year Operating margin (%) Range
Min: -4701.37   Max: 27.1
Current: 8.02

-4701.37
27.1
Net-margin (%) -6.78
SUPN's Net-margin (%) is ranked higher than
55% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. SUPN: -6.78 )
SUPN' s 10-Year Net-margin (%) Range
Min: -3127.3   Max: 6701.74
Current: -6.78

-3127.3
6701.74
ROE (%) -19.75
SUPN's ROE (%) is ranked higher than
55% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. SUPN: -19.75 )
SUPN' s 10-Year ROE (%) Range
Min: -202.72   Max: -138.13
Current: -19.75

-202.72
-138.13
ROA (%) -6.23
SUPN's ROA (%) is ranked higher than
57% of the 903 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. SUPN: -6.23 )
SUPN' s 10-Year ROA (%) Range
Min: -90.03   Max: 106.84
Current: -6.23

-90.03
106.84
ROC (Joel Greenblatt) (%) 153.23
SUPN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.80 vs. SUPN: 153.23 )
SUPN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3115.47   Max: 1356
Current: 153.23

-3115.47
1356
Revenue Growth (%) -64.50
SUPN's Revenue Growth (%) is ranked lower than
53% of the 730 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. SUPN: -64.50 )
SUPN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -64.5
Current: -64.5

EBITDA Growth (%) -45.30
SUPN's EBITDA Growth (%) is ranked lower than
51% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SUPN: -45.30 )
SUPN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -45.3
Current: -45.3

EPS Growth (%) -52.30
SUPN's EPS Growth (%) is ranked higher than
51% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. SUPN: -52.30 )
SUPN' s 10-Year EPS Growth (%) Range
Min: 0   Max: -52.3
Current: -52.3

» SUPN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SUPN Guru Trades in

SUPN Guru Trades in

Q2 2014

SUPN Guru Trades in Q2 2014

Louis Moore Bacon 100,000 sh (New)
Robert Bruce 100,000 sh (New)
» More
Q3 2014

SUPN Guru Trades in Q3 2014

Jim Simons 36,700 sh (New)
Robert Bruce 400,000 sh (+300%)
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Bruce 2014-09-30 Add 300%0.73%$7.99 - $11.13 $ 8.88-1%400000
Robert Bruce 2014-06-30 New Buy0.25%$7.32 - $10.85 $ 8.880%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.80
SUPN's P/B is ranked higher than
61% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. SUPN: 5.80 )
SUPN' s 10-Year P/B Range
Min: 2.61   Max: 18.63
Current: 5.8

2.61
18.63
P/S 4.00
SUPN's P/S is ranked higher than
72% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.92 vs. SUPN: 4.00 )
SUPN' s 10-Year P/S Range
Min: 3.34   Max: 139.8
Current: 4

3.34
139.8
EV-to-EBIT 42.31
SUPN's EV-to-EBIT is ranked higher than
73% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. SUPN: 42.31 )
SUPN' s 10-Year EV-to-EBIT Range
Min: -11.8   Max: 50.4
Current: 42.31

-11.8
50.4
Current Ratio 4.65
SUPN's Current Ratio is ranked higher than
84% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. SUPN: 4.65 )
SUPN' s 10-Year Current Ratio Range
Min: 1.51   Max: 7.26
Current: 4.65

1.51
7.26
Quick Ratio 4.15
SUPN's Quick Ratio is ranked higher than
85% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SUPN: 4.15 )
SUPN' s 10-Year Quick Ratio Range
Min: 1.51   Max: 7.26
Current: 4.15

1.51
7.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 30.96
SUPN's Price/Net Cash is ranked higher than
87% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SUPN: 30.96 )
SUPN' s 10-Year Price/Net Cash Range
Min: 4.19   Max: 62.83
Current: 30.96

4.19
62.83
Price/Net Current Asset Value 13.01
SUPN's Price/Net Current Asset Value is ranked higher than
85% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SUPN: 13.01 )
SUPN' s 10-Year Price/Net Current Asset Value Range
Min: 4.14   Max: 223.5
Current: 13.01

4.14
223.5
Price/Tangible Book 6.24
SUPN's Price/Tangible Book is ranked higher than
67% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. SUPN: 6.24 )
SUPN' s 10-Year Price/Tangible Book Range
Min: 3.85   Max: 19.29
Current: 6.24

3.85
19.29
Price/Median PS Value 0.12
SUPN's Price/Median PS Value is ranked higher than
100% of the 939 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.31 vs. SUPN: 0.12 )
SUPN' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 3.92
Current: 0.12

0.12
3.92
Earnings Yield (Greenblatt) 2.40
SUPN's Earnings Yield (Greenblatt) is ranked higher than
73% of the 878 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SUPN: 2.40 )
SUPN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 2.4
Current: 2.4

2
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S49.Germany
Supernus Pharmaceuticals Inc., was incorporated in Delaware on March 30, 2005. It is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market. The Company has a broad portfolio of drug development technologies consisting of six platforms that include the following: Microtrol, Solutrol (matrix delivery platform) and EnSoTrol. In addition to Oxtellar XR and Trokendi XR, the Company's proprietary technologies have been used in the following approved products: Carbatrol, Adderall XR, and Intuniv, marketed by Shire; Equetro, marketed by Validus Pharmaceuticals Inc.; Sanctura XR, marketed by Allergan, Inc.; Oracea, marketed by Galderma Laboratories, L.P.; and Orenitram. Oxtellar XR and Trokendi XR are novel extended release formulations of two well known and approved AEDs, oxcarbazepine and topiramate. The Company's psychiatry portfolio includes three product candidates for the treatment of impulsive aggression in patients with ADHD, ADHD or its coexisting conditions and one product candidate for depression, each of which is designed to bring important advancements in therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
Nasdaq stocks posting largest percentage increases Nov 21 2014
Supernus Sues Zydus for Infringement of Trokendi XR(R) Patents Nov 21 2014
4:13 pm Supernus Pharma sues Zydus for infringement of Trokendi XR Patents; patent protection for... Nov 21 2014
Supernus Sues Zydus for Infringement of Trokendi XR(R) Patents Nov 21 2014
SUPERNUS PHARMACEUTICALS INC Financials Nov 21 2014
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% Nov 19 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 12 2014
Supernus misses 3Q profit forecasts Nov 11 2014
Supernus misses 3Q profit forecasts Nov 11 2014
Supernus Announces Third Quarter 2014 Results Nov 11 2014
Supernus Announces Third Quarter 2014 Results Nov 11 2014
Q3 2014 Supernus Pharmaceuticals Inc Earnings Release - After Market Close Nov 11 2014
Supernus Announces Issuance of Fourth U.S. Patent Protecting Trokendi XR(R) Nov 07 2014
Supernus Announces Issuance of Fourth U.S. Patent Protecting Trokendi XR(R) Nov 07 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 05 2014
Supernus to Present at Two Investor Conferences Nov 04 2014
Supernus to Present at Two Investor Conferences Nov 04 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 30 2014
Supernus to Host Third Quarter 2014 Earnings Conference Call Oct 29 2014
Supernus to Host Third Quarter 2014 Earnings Conference Call Oct 29 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 24 2014
Supernus' Trokendi XR Faces Generic Threat from Zydus Oct 15 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 15 2014
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Oct 14 2014
Supernus Up, Files Lawsuit against Actavis for Trokendi XR Oct 06 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 03 2014
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents Oct 02 2014
Dr. Reddy's (RDY) Generic Xopenex Launched in the US Sep 25 2014
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 24 2014
Supernus Announces Fourth Quarter and Full Year 2013 Results Mar 12 2014
Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™ Mar 12 2014
Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call Feb 25 2014
Supernus to Present at Cowen and Company Healthcare Conference in March Feb 20 2014
Supernus at Citibank and RBC Global Healthcare Conferences in February Feb 07 2014
Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR® Feb 03 2014
Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R) Jan 07 2014
Supernus Announces Resignation of Board Member Dec 24 2013
Supernus Announces FDA Approval of Its Partner's Product, Orenitram(TM) Dec 23 2013
Supernus Posts Exciting Clinical Data Regarding Trokendi XR(TM) and Oxtellar XR(TM) on the Company... Dec 12 2013
Supernus to Present at Piper Jaffray Healthcare Conference in December Nov 21 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK